Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Mad2 who wrote (2033)	1/16/2000 12:20:00 AM
From: out_of_the_loop	Read Replies (2) \| Respond to of 5582

Mad2, I am not shooting you. The article is not, in my opinion, correct and neither is Dr. Romero. The licensable issue and the use of pleconaril for the common cold vs viral meningitis are two different issues. You can make fun of me if you wish but my academic credentials are better than many, although I have been in private practice for several years now, and there are academicians who already publicly support Zicam - and independent academicians performed the second clinicals on Zicam that included common cold treatment and prophylaxis. Sound bytes and data are two diiferent things. If you have the confidence that pleconaril will be the drug of choice for common colds based on what you have said, then behave accordingly. I just presented what I think is an accurate comparison of Zicam and pleconaril, something that is not new to this thread.